Functional, cognitive and behavioural effects of 5-MeO-DMT administered by intramuscular injection

This single-blind study aims to investigate the effects of intramuscularly (IM) administered 5-MeO-DMT on various aspects of human brain activity and well-being in healthy adults.

The trial, conducted by Swinburne University of Technology in Hawthorn, Australia, has been approved by the Swinburne University Human Research Ethics Committee. The study will involve 15 healthy volunteers aged between 18 and 40 years, with a good command of English and prior experience with psychedelics without adverse events.

Participants will undergo four dosing days, each spaced two weeks apart, involving IM administration of 5-MeO-DMT at doses of 3 mg, 6 mg, and 9 mg, as well as an inactive placebo.

The primary outcome will assess the acute and post-acute effects of 5-MeO-DMT on frequency oscillatory power bands using magnetoencephalography (MEG).

Secondary outcomes include assessing neurobiological activity, emotional regulation, decentering, suggestibility, social desirability, resilience, interoceptive awareness, satisfaction with life, symptoms of depression, anxiety and stress, mindfulness, self-regulation, spiritual bypassing, somatic symptoms, sleep measures, gratitude, personality, physical symptoms, occurrence of hallucinogen persisting perception disorder (HPPD), reactivation, adverse psychological effects, resting state cognition, challenge of experience, mystical experience, ego dissolution, acceptance promoting experience, emotional breakthrough, experiences of love, somatic experiences, avoidance-promoting experience, safety profile, and a range of sleep measures.

Data collection will occur at baseline, 3 days after each dosing session, then at 1 month and 3 months post-completion of the IM administration series. The study’s principal investigator is Prof Susan Rossell, who can be contacted for further information. The trial is not yet recruiting participants as of February 2024.

Topic Healthy Subjects
Compound 5-MeO-DMT Placebo
Country Australia
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Swinburne University of Technology
Swinburne University of Technology, located in Melbourne, Australia, is known for its focus on innovation, industry engagement, and social inclusion.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.